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Background
An effective HIV-1 vaccine will have to interfere with viral
transmission across a mucosal surface and prevent the
establishment of infection. The exact mechanism of the
infectious process at the mucosa is still poorly understood
as are the effects of bodily fluids on HIV-1 transmission.
Methods
We have studied the effects of human milk (HM) and
seminal plasma (SP) on interfering with the capture of
HIV-1 through binding to DC-SIGN on dendritic cells and
prevent the subsequent transfer of HIV-1 to CD4 cells.
HM and SP were tested in Raji-DC-SIGN and immature
dendritic cell transfer assays to determine interference
with HIV-1 capture and transfer. Fractionation and
MALDI-TOF biochemical analysis was utilized to identify
proteins with DC-SIGN binding activity.
Results
We identify that both HM and SP can potently block the
capture and transfer of HIV-1 through DC-SIGN. Through
our analysis we show that bile-salt stimulated lipase
(BSSL) in human milk and mucin6 in seminal plasma
have the capacity to inhibit HIV-1 transfer. BSSL is a
highly variable protein with its variant genotypic forms
showing different capacities to bind and inhibit. We also
demonstrate that there is a large degree of variation
between individuals for their HM or SP to prevent bind-
ing. Both these proteins have similarities in structure and
in their specific glycosylation patterns which likely facili-
tate their binding efficiencies.
Conclusion
We identify that BSSL and mucin6 have the capacity to
bind DC-SIGN and prevent HIV-1 capture at mucosal sur-
faces. By understanding their function and role in viral
transmission we can learn more on the infection process
but more importantly develop agents with either HIV-1
blocking capacity or which can target antigen at mucosal
surfaces to dendritic cells and for use as effective adjuvants
with mucosal vaccines.
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